Alaunos Ebitda vs Total Revenue Analysis

TCRT Stock

USD 1.09 0.04 3.81%

Alaunos Therapeutics financial indicator trend analysis is way more than just evaluating Alaunos Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alaunos Therapeutics is a good investment. Please check the relationship between Alaunos Therapeutics Ebitda and its Total Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Alaunos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.

Ebitda vs Total Revenue

Ebitda vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alaunos Therapeutics Ebitda account and Total Revenue. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Alaunos Therapeutics' Ebitda and Total Revenue is -0.57. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Alaunos Therapeutics, assuming nothing else is changed. The correlation between historical values of Alaunos Therapeutics' Ebitda and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Alaunos Therapeutics are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Ebitda i.e., Alaunos Therapeutics' Ebitda and Total Revenue go up and down completely randomly.

Correlation Coefficient

-0.57

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Ebitda

Total Revenue

Total revenue comprises all receipts Alaunos Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Alaunos Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alaunos Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Alaunos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.At this time, Alaunos Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 24.6 M in 2024, whereas Enterprise Value is likely to drop slightly above 10.3 M in 2024.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	740K	2.8M	2.3M	1.7M
Reconciled Depreciation	2.6M	2.8M	2.8M	1.9M

Cost Of Revenue Reconciled Depreciation

Alaunos Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Other Current Liab	Total Current Liabilities	Accounts Payable	Common Stock	Property Plant And Equipment Net	Other Current Assets	Short Term Investments	Current Deferred Revenue	Other Liab
Total Assets		-0.27	0.35	-0.93	-0.06	0.97	0.46	0.23	0.4	0.97	0.51	0.42	0.6	0.1	0.47	0.99	-0.5	0.8	0.74	0.36	0.54	0.35	0.56	0.58	0.22	0.1
Short Long Term Debt Total	-0.27		0.01	0.47	-0.68	-0.31	0.32	-0.23	-0.59	-0.31	-0.1	-0.52	-0.2	0.67	-0.27	-0.33	-0.23	-0.41	0.01	-0.08	0.13	0.54	-0.42	-0.35	0.46	-0.64
Total Stockholder Equity	0.35	0.01		-0.36	0.09	0.41	0.12	-0.35	-0.21	0.41	0.62	-0.29	-0.35	0.11	-0.59	0.35	-0.17	0.34	0.07	-0.26	0.29	0.39	-0.17	0.18	-0.07	-0.38
Net Debt	-0.93	0.47	-0.36		-0.17	-0.98	-0.16	-0.12	-0.56	-0.98	-0.38	-0.5	-0.64	0.12	-0.39	-0.96	0.44	-0.78	-0.57	-0.31	-0.25	-0.09	-0.46	-0.51	-0.02	-0.32
Retained Earnings	-0.06	-0.68	0.09	-0.17		0.08	-0.45	-0.09	0.47	0.08	-0.25	0.21	0.07	-0.98	-0.17	0.0	0.53	0.1	-0.22	-0.08	-0.23	-0.44	-0.21	0.43	-0.9	0.75
Cash	0.97	-0.31	0.41	-0.98	0.08		0.29	0.09	0.48	1.0	0.41	0.41	0.64	-0.02	0.37	0.98	-0.47	0.77	0.66	0.32	0.39	0.27	0.41	0.55	0.07	0.23
Non Current Assets Total	0.46	0.32	0.12	-0.16	-0.45	0.29		0.52	-0.19	0.29	0.48	-0.01	0.04	0.44	0.2	0.35	-0.26	0.36	0.6	0.42	0.75	0.77	0.23	0.34	0.38	-0.42
Non Currrent Assets Other	0.23	-0.23	-0.35	-0.12	-0.09	0.09	0.52		0.34	0.09	0.01	0.59	0.22	0.01	0.46	0.18	-0.15	0.19	0.25	0.63	0.15	-0.15	0.53	0.19	0.2	0.07
Other Assets	0.4	-0.59	-0.21	-0.56	0.47	0.48	-0.19	0.34		0.48	-0.37	0.88	0.63	-0.53	0.38	0.45	-0.32	0.44	0.31	0.42	-0.21	-0.48	0.25	0.41	-0.4	0.79
Cash And Short Term Investments	0.97	-0.31	0.41	-0.98	0.08	1.0	0.29	0.09	0.48		0.41	0.41	0.64	-0.02	0.37	0.98	-0.47	0.77	0.66	0.32	0.39	0.27	0.41	0.55	0.07	0.23
Net Receivables	0.51	-0.1	0.62	-0.38	-0.25	0.41	0.48	0.01	-0.37	0.41		-0.25	-0.27	0.36	-0.03	0.47	-0.17	0.51	0.18	-0.14	0.54	0.55	0.4	0.21	0.31	-0.53
Common Stock Shares Outstanding	0.42	-0.52	-0.29	-0.5	0.21	0.41	-0.01	0.59	0.88	0.41	-0.25		0.61	-0.29	0.48	0.45	-0.34	0.34	0.3	0.42	-0.07	-0.46	0.52	0.34	-0.04	0.55
Non Current Liabilities Total	0.6	-0.2	-0.35	-0.64	0.07	0.64	0.04	0.22	0.63	0.64	-0.27	0.61		-0.16	0.7	0.63	-0.25	0.31	0.5	0.44	0.05	-0.12	0.37	0.32	0.11	0.57
Other Stockholder Equity	0.1	0.67	0.11	0.12	-0.98	-0.02	0.44	0.01	-0.53	-0.02	0.36	-0.29	-0.16		0.03	0.05	-0.54	-0.05	0.19	0.01	0.25	0.5	0.15	-0.45	0.88	-0.83
Total Liab	0.47	-0.27	-0.59	-0.39	-0.17	0.37	0.2	0.46	0.38	0.37	-0.03	0.48	0.7	0.03		0.47	-0.24	0.32	0.48	0.48	0.21	-0.12	0.74	0.29	0.29	0.32
Total Current Assets	0.99	-0.33	0.35	-0.96	0.0	0.98	0.35	0.18	0.45	0.98	0.47	0.45	0.63	0.05	0.47		-0.49	0.79	0.7	0.32	0.47	0.26	0.56	0.57	0.18	0.16
Intangible Assets	-0.5	-0.23	-0.17	0.44	0.53	-0.47	-0.26	-0.15	-0.32	-0.47	-0.17	-0.34	-0.25	-0.54	-0.24	-0.49		-0.48	-0.51	-0.33	-0.08	-0.18	-0.27	-0.04	-0.4	0.22
Other Current Liab	0.8	-0.41	0.34	-0.78	0.1	0.77	0.36	0.19	0.44	0.77	0.51	0.34	0.31	-0.05	0.32	0.79	-0.48		0.69	0.33	0.34	0.27	0.45	0.52	-0.08	0.16
Total Current Liabilities	0.74	0.01	0.07	-0.57	-0.22	0.66	0.6	0.25	0.31	0.66	0.18	0.3	0.5	0.19	0.48	0.7	-0.51	0.69		0.57	0.65	0.5	0.32	0.56	0.19	0.08
Accounts Payable	0.36	-0.08	-0.26	-0.31	-0.08	0.32	0.42	0.63	0.42	0.32	-0.14	0.42	0.44	0.01	0.48	0.32	-0.33	0.33	0.57		0.13	0.01	0.16	0.23	0.08	0.29
Common Stock	0.54	0.13	0.29	-0.25	-0.23	0.39	0.75	0.15	-0.21	0.39	0.54	-0.07	0.05	0.25	0.21	0.47	-0.08	0.34	0.65	0.13		0.75	0.29	0.64	0.24	-0.3
Property Plant And Equipment Net	0.35	0.54	0.39	-0.09	-0.44	0.27	0.77	-0.15	-0.48	0.27	0.55	-0.46	-0.12	0.5	-0.12	0.26	-0.18	0.27	0.5	0.01	0.75		-0.13	0.25	0.29	-0.53
Other Current Assets	0.56	-0.42	-0.17	-0.46	-0.21	0.41	0.23	0.53	0.25	0.41	0.4	0.52	0.37	0.15	0.74	0.56	-0.27	0.45	0.32	0.16	0.29	-0.13		0.27	0.44	-0.02
Short Term Investments	0.58	-0.35	0.18	-0.51	0.43	0.55	0.34	0.19	0.41	0.55	0.21	0.34	0.32	-0.45	0.29	0.57	-0.04	0.52	0.56	0.23	0.64	0.25	0.27		-0.38	0.39
Current Deferred Revenue	0.22	0.46	-0.07	-0.02	-0.9	0.07	0.38	0.2	-0.4	0.07	0.31	-0.04	0.11	0.88	0.29	0.18	-0.4	-0.08	0.19	0.08	0.24	0.29	0.44	-0.38		-0.67
Other Liab	0.1	-0.64	-0.38	-0.32	0.75	0.23	-0.42	0.07	0.79	0.23	-0.53	0.55	0.57	-0.83	0.32	0.16	0.22	0.16	0.08	0.29	-0.3	-0.53	-0.02	0.39	-0.67

Click cells to compare fundamentals

Alaunos Therapeutics Account Relationship Matchups

Alaunos Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	109.1M	146.3M	94.9M	64.9M	8.3M	7.8M
Total Stockholder Equity	95.0M	124.0M	58.1M	38.6M	6.3M	6.0M
Net Debt	(77.4M)	(110.3M)	(46.7M)	(19.5M)	(6.1M)	(6.4M)
Retained Earnings	(684.1M)	(764.1M)	(842.9M)	(880.6M)	(915.8M)	(870.0M)
Cash	79.7M	115.1M	76.1M	39.1M	6.1M	5.8M
Non Current Assets Total	3.6M	15.8M	16.0M	11.1M	2K	1.9K
Non Currrent Assets Other	9.7M	240K	875K	673K	542K	0.0
Other Assets	240K	875K	673K	542K	1.0	0.95
Cash And Short Term Investments	79.7M	115.1M	76.1M	39.1M	6.1M	5.8M
Net Receivables	3.3M	4.7M	1.1M	4K	1K	950.0
Common Stock Shares Outstanding	11.2M	14.0M	14.3M	14.5M	16.0M	15.2M
Liabilities And Stockholders Equity	109.1M	146.3M	94.9M	64.9M	8.3M	7.8M
Non Current Liabilities Total	4K	1.6M	4.0M	20.8M	2.2M	0.0
Other Stockholder Equity	779.0M	887.9M	900.7M	918.9M	922.1M	968.2M
Total Liab	109.1M	22.4M	36.8M	26.4M	2.0M	1.9M
Total Current Assets	105.5M	130.6M	78.8M	53.8M	8.3M	7.8M
Other Current Liab	10.8M	16.6M	6.1M	5.5M	1.3M	1.3M
Total Current Liabilities	12.5M	18.4M	16.0M	24.2M	2.0M	1.9M
Accounts Payable	906K	960K	1.4M	1.4M	616K	585.2K
Common Stock	182K	215K	216K	240K	16K	15.2K
Property Plant And Equipment Net	3.4M	14.9M	15.4M	10.6M	2K	1.9K
Other Current Assets	22.4M	10.9M	1.7M	799K	2.2M	2.1M
Net Tangible Assets	95.0M	124.0M	58.1M	38.6M	44.3M	55.8M
Property Plant Equipment	3.4M	14.9M	15.4M	8.5M	9.7M	8.1M
Net Invested Capital	95.0M	124.0M	82.2M	55.3M	6.3M	6.0M
Capital Stock	182K	215K	216K	240K	16K	15.2K
Net Working Capital	93.0M	112.2M	62.8M	29.6M	6.3M	6.0M

Pair Trading with Alaunos Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alaunos Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alaunos Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Alaunos Stock

0.85

Equillium

Pair Corr

Moving against Alaunos Stock

0.53

VALN

Valneva SE ADR

Pair Corr

The ability to find closely correlated positions to Alaunos Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alaunos Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alaunos Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alaunos Therapeutics to buy it.

The correlation of Alaunos Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alaunos Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alaunos Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Alaunos Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Alaunos Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Alaunos Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Alaunos Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Alaunos Therapeutics Stock:

How To Invest In Alaunos

Details

Is Alaunos Stock a good investment?

Details

What is Alaunos Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Alaunos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.

You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Alaunos Stock analysis

When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.

Is Alaunos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alaunos Therapeutics. If investors know Alaunos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alaunos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(32.48)

Quarterly Revenue Growth

(0.91)

Return On Assets

(0.49)

Return On Equity

(1.57)

The market value of Alaunos Therapeutics is measured differently than its book value, which is the value of Alaunos that is recorded on the company's balance sheet. Investors also form their own opinion of Alaunos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alaunos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alaunos Therapeutics' market value can be influenced by many factors that don't directly affect Alaunos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alaunos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alaunos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alaunos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alaunos Ebitda vs Total Revenue Analysis

Ebitda vs Total Revenue

Ebitda vs Total Revenue Correlation Analysis

Correlation Coefficient

Ebitda

Total Revenue

Alaunos Therapeutics fundamental ratios Correlations

Alaunos Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alaunos Therapeutics fundamental ratios Accounts

Pair Trading with Alaunos Therapeutics

Moving together with Alaunos Stock

Moving against Alaunos Stock

Complementary Tools for Alaunos Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Total Current Assets	+ 0.98	Cash
Total Current Assets	+ 0.98	Cash And Short Term Investments
Cash	+ 0.97	Total Assets
Cash And Short Term Investments	+ 0.97	Total Assets

Other Stockholder Equity	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Total Current Assets	- 0.96	Net Debt
Net Debt	- 0.93	Total Assets
Current Deferred Revenue	- 0.9	Retained Earnings